about
Cytosolic aspartate aminotransferase, a new partner in adipocyte glyceroneogenesis and an atypical target of thiazolidinedioneCoagulation or excision of ovarian endometriomas?Research resource: genome-wide profiling of methylated promoters in endometriosis reveals a subtelomeric location of hypermethylation.ABO and Rhesus blood groups and risk of endometriosis in a French Caucasian population of 633 patients living in the same geographic area.An update on the pharmacological management of endometriosis.Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis.FOXL2 in human endometrium: hyperexpressed in endometriosis.Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.Endometriosis and infertility: pathophysiology and management.Increased serum cancer antigen-125 is a marker for severity of deep endometriosis.Increased serum oxidative stress markers in women with uterine leiomyomaManagement of ovarian endometriomas.Low birth weight is strongly associated with the risk of deep infiltrating endometriosis: results of a 743 case-control study.The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice.Soluble ligands for the NKG2D receptor are released during endometriosis and correlate with disease severity.Evidence for asymmetric distribution of sciatic nerve endometriosis.Evidence for asymmetric distribution of lower intestinal tract endometriosis.Surgical management of deeply infiltrating endometriosis: an update.Diagnosis of endometriosis with imaging: a review.Peritoneal fluid flow influences anatomical distribution of endometriotic lesions: why Sampson seems to be right.Factors and Regional Differences Associated with Endometriosis: A Multi-Country, Case-Control Study.Reactive oxygen species controls endometriosis progression.Cancer and fecundity issues mandate a multidisciplinary approach.HIV-positive patients undertaking ART have longer infertility histories than age-matched control subjects.Multiplying recipients paired with oocyte donors optimizes the use of donated oocytes.Markers of adult endometriosis detectable in adolescence.The value of growth hormone supplements in ART for poor ovarian responders.New treatment strategies and emerging drugs in endometriosis.Inflammation: a link between endometriosis and preterm birth.Retrieving oocytes from small non-stimulated follicles in polycystic ovary syndrome (PCOS): in vitro maturation (IVM) is not indicated in the new GnRH antagonist era.Risk and safety management in infertility and assisted reproductive technology (ART): from the doctor's office to the ART procedure.An update on the pharmacological management of adenomyosis.Dual ovarian stimulation is a new viable option for enhancing the oocyte yield when the time for assisted reproductive technnology is limited.Deep endometriosis infiltrating the recto-sigmoid: critical factors to consider before management.Pathogenetic Mechanisms of Deep Infiltrating Endometriosis.MAP kinases and the inflammatory signaling cascade as targets for the treatment of endometriosis?Relationship between the magnetic resonance imaging appearance of adenomyosis and endometriosis phenotypes.Dysregulation of the ADAM17/Notch signalling pathways in endometriosis: from oxidative stress to fibrosis.Serum Osteopontin Levels Are Decreased in Focal Adenomyosis.Surgical treatment: Myomectomy and hysterectomy; Endoscopy: A major advancement.
P50
Q24307812-70B66CF3-2977-411E-9837-F01D62461E9BQ30896418-174E1B6A-C851-4293-824B-E6407E23E459Q33637255-2D8656FB-5B88-4197-9845-9ABAFB3C5BEBQ34162046-A004B41A-6628-484F-82F4-326E4631015CQ34324798-2652450D-1FB1-438A-9A2A-0D86D36C2B83Q34358271-A07C720A-596D-45D2-A8C7-59A922A728CCQ34403753-93551CD4-471A-42BD-90EB-ADCD148A4E09Q34503338-283DDA04-2238-44F2-9A9B-4812C562A18AQ34622946-A1B55F14-8559-455C-BA56-0AADD0B3DB14Q34666681-455E2B2F-60BC-4241-85A3-BCA9C48C7666Q34951145-4A71F423-6D44-44F3-A982-3792286E36F0Q35033103-BD705A4B-4EB7-4FBE-AA72-FACFDDEC32AFQ35094917-97E76433-2CDF-44F8-A558-4A6DAC96E370Q35168199-FED88A85-3475-4D92-AD90-2D3ECC786A00Q35181683-2888B892-83E8-49E7-933D-1375C1FB730EQ35195383-E757363F-9277-478F-A7B2-19D2AC2A20D7Q35937000-B5C2E7DB-D1AA-4CDB-960C-5FB36FFF127BQ36054373-91C9FF21-7A28-4F79-B0F7-A1F9A017B93DQ36254929-53587732-C1F4-49F9-B702-681079C38981Q37108999-567EDD3F-6B45-4599-9DE8-9B47961D9175Q37143767-1045EC68-E93E-4D80-835E-E4F4B86C0D05Q37257155-8FE243C5-8F59-4214-88CE-1B7849A04352Q37387990-95EFF0D5-FF90-44C1-9528-9CE2178D16ECQ37802518-F5310941-7732-4B1C-9EE0-B9BFED521E2EQ37837198-82B7D1FF-B393-40D9-8B7A-A78E14ADC6BEQ37920430-D2D949A1-8519-4BE2-949C-A2769F212C5FQ37950637-3EBD1B72-FB8B-4C03-9D9F-EC26E915D767Q37996102-5BFCF298-B8A9-4B77-BA8C-1FBF94311931Q38015545-BA93446E-A747-4670-A1E2-22AB98ED6B78Q38030737-286D7419-006E-4C89-845B-93E9B39A0DD3Q38160568-F99401F3-DE9B-424D-8389-9B9DD0FCE70EQ38246723-E3050012-D4E9-45BE-928B-A87DAEDB84E1Q38303541-EEB0A42A-707B-4103-A868-9490247A690BQ38331374-F8F2DC78-1F5D-4D00-AD69-BA12D6282A9AQ38546195-1EB233FD-6E9B-4364-8F47-1C2AC7441DDEQ38590189-7653E297-CD6F-4600-BECB-DF0B32E706BBQ38683119-DCF0429C-0E4B-4970-A537-9370D57D70A1Q38795582-4F14DFE2-15F1-4122-98A2-DCE139B0CE65Q38817047-55BA760F-A702-4D80-A510-FB2F8B7BCD1AQ38892599-0959C5B4-3441-4328-8F5F-711545970479
P50
name
Charles Chapron
@en
Charles Chapron
@nl
type
label
Charles Chapron
@en
Charles Chapron
@nl
prefLabel
Charles Chapron
@en
Charles Chapron
@nl